Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Open Access
- 9 November 2017
- journal article
- research article
- Published by Springer Nature in Skeletal Radiology
- Vol. 47 (3) , 363-367
Abstract
Objective To determine and compare the value of 18F–fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) to blind bone marrow biopsy (BMB) of the posterior iliac crest in detecting metastatic bone marrow involvement in newly diagnosed Ewing sarcoma. Materials and methods This retrospective study included 20 patients with newly diagnosed Ewing sarcoma who underwent pretreatment FDG-PET/CT and a total of 38 blind BMBs (two unilateral and 18 bilateral) of the posterior iliac crest. FDG-PET/CT scans were evaluated for bone marrow involvement, both in the posterior iliac crest and other sites, and compared to blind BMB results. Results FDG-PET/CT was positive for bone marrow involvement in 7/38 posterior iliac crests, whereas BMB was positive in 5/38 posterior iliac crests. FDG-PET/CT and BMB results in the posterior iliac crest agreed in 36/38 cases (94.7%, 95% confidence interval [CI]: 82.7–98.5%). On a patient level, FDG-PET/CT was positive for bone marrow involvement in 4/20 patients, whereas BMB of the posterior iliac crest was positive in 3/20 patients. On a patient level, FDG-PET/CT and BMB results agreed in 19/20 patients (95.0%, 95% CI: 76.4–99.1%). The only discrepancies between FDG-PET/CT and BMB were observed in two BMBs of one patient. Both BMBs in this patient were negative, whereas FDG-PET/CT indicated bilateral posterior iliac crest involvement and also extensive bone marrow involvement elsewhere. Conclusions FDG-PET/CT appears to be a valuable method for metastatic bone marrow assessment in newly diagnosed Ewing sarcoma. The routine use of blind BMB of the posterior iliac crest should be reconsidered when FDG-PET/CT is available.Keywords
Funding Information
- University Medical Center Groningen (UMCG)
This publication has 11 references indexed in Scilit:
- The Role of 18 F-FDG-PET/CT in Pediatric SarcomaSeminars in Nuclear Medicine, 2017
- NCCN Guidelines Insights: Bone Cancer, Version 2.2017Journal of the National Comprehensive Cancer Network, 2017
- Ewing Sarcoma: Current Management and Future Approaches Through CollaborationJournal of Clinical Oncology, 2015
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Effect of blind bone marrow biopsy on FDG-PET/CT interpretation of the posterior iliac crest in diffuse large B-cell lymphomaHematological Oncology, 2014
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing SarcomaPediatric Blood & Cancer, 2012
- Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 TrialJournal of Clinical Oncology, 2010
- Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 DecadesJournal of Pediatric Hematology/Oncology, 2008
- Bone marrow biopsy morbidity: review of 2003: Table 1Journal of Clinical Pathology, 2005